{"id":{"repo_id":"qu-belfast","oai_identifier":"oai:pure.qub.ac.uk/portal:studenttheses/ffbe3726-cf85-4f46-9e59-27d576b831fe"},"canonical_url":"https://search.dev.ndltd.org/etd/qu-belfast/oai:pure.qub.ac.uk/portal:studenttheses/ffbe3726-cf85-4f46-9e59-27d576b831fe","repository":{"repo_id":"qu-belfast","name":"Queen's University Belfast","base_url":"https://pureadmin.qub.ac.uk/ws/oai"},"display":{"title":"An antimicrobial peptide QUB-1925 from scorpion venom of Androctonus bicolor: molecular cloning of biosynthetic precursor-encoding cDNA and bioactivity study","abstract":"Owing to the prominent biological diversity and potency, venoms of scorpion have attached to a starting point for drug discovery. This thesis focused on a novel antimicrobial peptide discovered from Androctonus bicolor. The QUB-1925 precursor-encoding cDNA was cloned by “shotgun” cloning of the venom-derived cDNA library, and the peptide was chemically synthesised by using the solid phase peptide synthesiser. Reverse phase high performance liquid chromatography (RP-HPLC) and LCQ Fleet ion-trap mass spectrometer were employed to purify the crude synthesised peptide and confirm the identity of this peptide, respevtively. Finally, the purified peptide was used to perform antimicrobial assays, haemolysis assay, and anti-tumour cell assays. <br/><br/>QUB-1925 presented inhibition effect on gram-positive bacteria, S. aureus, and gram-negative bacterium, E. coli, but little effect against the fungi, C. albicans. More importantly, QUB-1925 was found to induce a very low level of haemolysis at the minimal inhibitory concentration (MIC) of 8 μM ( against S.aureus) and 32μM (against E.coli), respectively. Moreover, QUB-1925 exhibited weak anti-proliferative activities against the human cancer cell lines PC-3, H-23, and U251MG. These data suggests that QUB-1925 has the potential to be a broad-spectrum antibiotic with low level of haemolytic activity. However, this cytotoxicity can not be ignorable. Future studies on the modification of AMP discovered from scorpion venom are therefore recommended.<br/><br/><i>Thesis embargoed until 31st October 2024 </i>","abstract_html":"Owing to the prominent biological diversity and potency, venoms of scorpion have attached to a starting point for drug discovery. This thesis focused on a novel antimicrobial peptide discovered from Androctonus bicolor. The QUB-1925 precursor-encoding cDNA was cloned by “shotgun” cloning of the venom-derived cDNA library, and the peptide was chemically synthesised by using the solid phase peptide synthesiser. Reverse phase high performance liquid chromatography (RP-HPLC) and LCQ Fleet ion-trap mass spectrometer were employed to purify the crude synthesised peptide and confirm the identity of this peptide, respevtively. Finally, the purified peptide was used to perform antimicrobial assays, haemolysis assay, and anti-tumour cell assays. &lt;br/&gt;&lt;br/&gt;QUB-1925 presented inhibition effect on gram-positive bacteria, S. aureus, and gram-negative bacterium, E. coli, but little effect against the fungi, C. albicans. More importantly, QUB-1925 was found to induce a very low level of haemolysis at the minimal inhibitory concentration (MIC) of 8 μM ( against S.aureus) and 32μM (against E.coli), respectively. Moreover, QUB-1925 exhibited weak anti-proliferative activities against the human cancer cell lines PC-3, H-23, and U251MG. These data suggests that QUB-1925 has the potential to be a broad-spectrum antibiotic with low level of haemolytic activity. However, this cytotoxicity can not be ignorable. Future studies on the modification of AMP discovered from scorpion venom are therefore recommended.&lt;br/&gt;&lt;br/&gt;&lt;i&gt;Thesis embargoed until 31st October 2024 &lt;/i&gt;","abstract_has_math":false,"creators":["Wang, Aoao"],"institution":"Queen's University Belfast","degree_name":"Master of Philosophy","degree_level":"Masters Thesis","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Chen, Tianbao","Zhou, Mei","Wang, Lei"],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-12","date_published":"2019-12","updated_at":"2026-07-24T03:55:05Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["oai:pure.qub.ac.uk/portal:studenttheses/ffbe3726-cf85-4f46-9e59-27d576b831fe"],"render_values":[{"text":"oai:pure.qub.ac.uk/portal:studenttheses/ffbe3726-cf85-4f46-9e59-27d576b831fe","href":null,"code":true}]}]},"links":{"outbound_url":"https://pure.qub.ac.uk/en/studentTheses/ffbe3726-cf85-4f46-9e59-27d576b831fe","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Chen, Tianbao","Zhou, Mei","Wang, Lei"]},{"key":"dc:creator","label":"Author","values":["Wang, Aoao"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019-12"]},{"key":"dc:date.issued","label":"Date","values":["2019-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["School of Pharmacy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["Queen's University Belfast"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://pure.qub.ac.uk/en/studentTheses/ffbe3726-cf85-4f46-9e59-27d576b831fe"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Masters Thesis"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["Master of Philosophy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights.embargodate","label":"Dc Rights Embargodate","values":["2024-10-31"]},{"key":"dc:rights.embargoreason","label":"Dc Rights Embargoreason","values":["/dk/atira/pure/core/document/studentthesisembargoreason/publicationissues"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["oai:pure.qub.ac.uk/portal:studenttheses/ffbe3726-cf85-4f46-9e59-27d576b831fe","https://pure.qub.ac.uk/en/studentTheses/ffbe3726-cf85-4f46-9e59-27d576b831fe"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://pure.qub.ac.uk/files/200223501/QUB1925_0209final_.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Owing to the prominent biological diversity and potency, venoms of scorpion have attached to a starting point for drug discovery. This thesis focused on a novel antimicrobial peptide discovered from Androctonus bicolor. The QUB-1925 precursor-encoding cDNA was cloned by “shotgun” cloning of the venom-derived cDNA library, and the peptide was chemically synthesised by using the solid phase peptide synthesiser. Reverse phase high performance liquid chromatography (RP-HPLC) and LCQ Fleet ion-trap mass spectrometer were employed to purify the crude synthesised peptide and confirm the identity of this peptide, respevtively. Finally, the purified peptide was used to perform antimicrobial assays, haemolysis assay, and anti-tumour cell assays. <br/><br/>QUB-1925 presented inhibition effect on gram-positive bacteria, S. aureus, and gram-negative bacterium, E. coli, but little effect against the fungi, C. albicans. More importantly, QUB-1925 was found to induce a very low level of haemolysis at the minimal inhibitory concentration (MIC) of 8 μM ( against S.aureus) and 32μM (against E.coli), respectively. Moreover, QUB-1925 exhibited weak anti-proliferative activities against the human cancer cell lines PC-3, H-23, and U251MG. These data suggests that QUB-1925 has the potential to be a broad-spectrum antibiotic with low level of haemolytic activity. However, this cytotoxicity can not be ignorable. Future studies on the modification of AMP discovered from scorpion venom are therefore recommended.<br/><br/><i>Thesis embargoed until 31st October 2024 </i>"]},{"key":"dc:title","label":"Title","values":["An antimicrobial peptide QUB-1925 from scorpion venom of Androctonus bicolor: molecular cloning of biosynthetic precursor-encoding cDNA and bioactivity study"]}]}],"canonical_facts":{"dc:contributor.advisor":["Chen, Tianbao","Zhou, Mei","Wang, Lei"],"dc:creator":["Wang, Aoao"],"dc:date":["2019-12"],"dc:date.issued":["2019-12"],"dc:description.abstract":["Owing to the prominent biological diversity and potency, venoms of scorpion have attached to a starting point for drug discovery. This thesis focused on a novel antimicrobial peptide discovered from Androctonus bicolor. The QUB-1925 precursor-encoding cDNA was cloned by “shotgun” cloning of the venom-derived cDNA library, and the peptide was chemically synthesised by using the solid phase peptide synthesiser. Reverse phase high performance liquid chromatography (RP-HPLC) and LCQ Fleet ion-trap mass spectrometer were employed to purify the crude synthesised peptide and confirm the identity of this peptide, respevtively. Finally, the purified peptide was used to perform antimicrobial assays, haemolysis assay, and anti-tumour cell assays. <br/><br/>QUB-1925 presented inhibition effect on gram-positive bacteria, S. aureus, and gram-negative bacterium, E. coli, but little effect against the fungi, C. albicans. More importantly, QUB-1925 was found to induce a very low level of haemolysis at the minimal inhibitory concentration (MIC) of 8 μM ( against S.aureus) and 32μM (against E.coli), respectively. Moreover, QUB-1925 exhibited weak anti-proliferative activities against the human cancer cell lines PC-3, H-23, and U251MG. These data suggests that QUB-1925 has the potential to be a broad-spectrum antibiotic with low level of haemolytic activity. However, this cytotoxicity can not be ignorable. Future studies on the modification of AMP discovered from scorpion venom are therefore recommended.<br/><br/><i>Thesis embargoed until 31st October 2024 </i>"],"dc:identifier":["oai:pure.qub.ac.uk/portal:studenttheses/ffbe3726-cf85-4f46-9e59-27d576b831fe","https://pure.qub.ac.uk/en/studentTheses/ffbe3726-cf85-4f46-9e59-27d576b831fe"],"dc:identifier.uri":["https://pure.qub.ac.uk/files/200223501/QUB1925_0209final_.pdf"],"dc:language":["eng"],"dc:publisher.department":["School of Pharmacy"],"dc:publisher.institution":["Queen's University Belfast"],"dc:relation.isreferencedby":["https://pure.qub.ac.uk/en/studentTheses/ffbe3726-cf85-4f46-9e59-27d576b831fe"],"dc:rights.embargodate":["2024-10-31"],"dc:rights.embargoreason":["/dk/atira/pure/core/document/studentthesisembargoreason/publicationissues"],"dc:title":["An antimicrobial peptide QUB-1925 from scorpion venom of Androctonus bicolor: molecular cloning of biosynthetic precursor-encoding cDNA and bioactivity study"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["Masters Thesis"],"dc:type.qualificationname":["Master of Philosophy"]},"updated_at":"2026-07-24T03:55:05Z"}